Estimating probability of germline mismatch repair mutations in colorectal cancer patients with microsatellite stable tumors by Everett, Jessica N et al.
POSTER PRESENTATION Open Access
Estimating probability of germline mismatch
repair mutations in colorectal cancer patients
with microsatellite stable tumors
Jessica N Everett1*, Victoria M Raymond1, Michele Gornick2, Rajesh S Mangrulkar1, Ignacio Blanco3,
Stephen B Gruber4
From 14th Annual Meeting of the Collaborative Group of the Americas on Inherited Colorectal Cancer
Dallas, TX, USA. 12-13 October 2010
Background
Microsatellite instability (MSI) is a hallmark of DNA
mismatch repair (MMR) deficiency and is an established
screening tool for identifying Lynch syndrome in color-
ectal cancer populations [1]. However, MSI testing is
neither perfectly sensitive nor specific to detect Lynch
Syndrome, and germline MMR mutations have been
reported in patients with microsatellite stable (MSS)
tumors [2]. The value of germline MMR testing in
patients with MSS tumors may vary based on family his-
tory, and data is needed to guide choices about when to
offer testing in high risk clinic settings.
Materials and methods
From 2002-2009, high risk patients presenting to the
Cancer Genetics Clinics at the University of Michigan
and the Catalan Institute of Oncology in Barcelona,
Spain were evaluated for Lynch syndrome and included
in the present study. Patients with MSS colorectal tumors
who also had germline MMR testing were eligible for
analysis. We calculated risk for MMR mutation using
MMRPro v.5.1 [3] at baseline, after MSI testing, and after
germline MMR testing. Modified likelihood ratios were
estimated to evaluate the utility of germline testing in
patients with MSS tumors based on the strength of the
family history [4].
Results
Germline MMR mutations were identified in 5/44 (11.4%)
patients with MSS tumors. Two of the mutations were
identified in patients from families that met the Amster-
dam Criteria (AC I/II), whereas 3 mutations were found in
patients from families that were AC I/II negative. The
modified likelihood for a germline mutation (+LRmod) in
an AC I/II patient was 1.56 (95% CI: 0.47 - 5.18) and the
modified negative likelihood ratio (-LRmod) for a patient
not meeting the AC I/II criteria was 0.81 (95% CI: 0.39 -
1.69). We quantified the meaning of the AC I/II criteria to
guide clinical choices about genetic testing in MSS tumors
by multiplying the pretest odds by the +LRmod and the
-LRmod. The probability of a mutation was modified from
a baseline of 11.4% to 16.7% in AC I/II families, compared
to 9.4% in AC I/II-negative families.
Conclusions
Germline MMR testing in high risk patients with MSS
colorectal tumors identifies mutations in a small, but
meaningful proportion of patients. The diagnostic yield
is dependent on the strength of the family history. Mod-
ified likelihood ratios can be helpful to quantify the
probability of a positive gene test for Lynch Syndrome,
and can be applied to pre-test probabilities derived from
clinical models.
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